Exclusive Summary

• Backed by top-tier US-FDA and UK-MHRA GMP certifications, plus an existing US registration, enabling immediate distribution in the US and fast-track, clinical-exempt registration in emerging markets relying on reference approvals.
• Targets a massive demographic including the primary 70% HR+ sub-group of the 2.3 million annual global breast cancer cases, augmented by a rapidly growing off-label use as a first-line ovulation induction for PCOS infertility.
• Maximizes distributor profit margins and tender competitiveness by leveraging China's unmatched scalable manufacturing to offer highly cost-effective pricing compared to originators and regional generics.
• Offers an upfront simple 'Distribution' partnership model with zero patent restrictions, allowing overseas pharma players a 'plug-and-play' approach to commercialize a highly-demanded WHO Essential Medicine without R&D wait times.